{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T22:54:03Z","timestamp":1775429643319,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Patients with chronic kidney disease (CKD) frequently experience cardiovascular events, and as per current therapeutic guidelines, renin-angiotensin system inhibitors (RASi) can protect the cardiovascular system in those with proteinuric CKD. Effectiveness of RASi in treating non-proteinuric CKD is still unknown, yet. In order to evaluate the impact of RASi on cardiovascular morbidity and mortality in patients with non-proteinuric CKD, we performed a post-hoc analysis of the Frontier of Renal Outcome Modification-Japan study. A urine protein-to-creatinine ratio less than 0.15\u2009g\/g or negative\/trace protein on urinalysis was considered as non-proteinuric CKD. Those who have undergone dialysis, kidney transplant recipients, and patients who refused to give their consent were excluded. A composite of cardiovascular events, initiation of renal replacement therapy, and all-cause mortality was studied as the primary outcome. Of 2379 patients with CKD, 630 met the criteria for non-proteinuric CKD. Among them, 490 used RASi, and 140 did not. Although the RASi group was considerably younger and had a higher prevalence of hypertension and calcium channel blocker use, baseline characteristics were comparable. 12.1% of the control group and 16.7% of the RASi group experienced the primary outcome during follow-up, with no significant difference (adjusted HR: 1.37; 95% CI: 0.81\u20132.31). Secondary outcomes and analyses of RASi use for the whole observation period did not show any significant differences (adjusted HR: 0.81; 95% CI: 0.43\u20131.56). These results imply that RASi was not linked to a decreased risk of mortality or long-term events in those with nonproteinuric CKD.<\/jats:p>","DOI":"10.1038\/s41440-025-02536-x","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T02:32:39Z","timestamp":1768357959000},"page":"1161-1169","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Renin-angiotensin system inhibitor use and cardio-renal outcomes in non-proteinuric chronic kidney disease: a post-hoc analysis of the Frontier of Renal Outcome Modification-Japan study"],"prefix":"10.1038","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0733-5843","authenticated-orcid":false,"given":"Hirohito","family":"Sugawara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiryu","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chie","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiei","family":"Narita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoichi","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Wada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Wada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetoshi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiro","family":"Yamagata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Ogata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"2536_CR1","doi-asserted-by":"publisher","first-page":"e342","DOI":"10.1016\/S2214-109X(24)00050-0","volume":"12","author":"M Jadoul","year":"2024","unstructured":"Jadoul M, Aoun M, Masimango Imani M. The major global burden of chronic kidney disease. Lancet Glob Health. 2024;12:e342\u20133.","journal-title":"Lancet Glob Health"},{"key":"2536_CR2","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","volume":"143","author":"J Jankowski","year":"2021","unstructured":"Jankowski J, Floege J, Fliser D, B\u00f6hm M, Marx N. Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation. 2021;143:1157\u201372.","journal-title":"Circulation"},{"key":"2536_CR3","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/bcp.12104","volume":"76","author":"P Cravedi","year":"2013","unstructured":"Cravedi P, Remuzzi G. Pathophysiology of proteinuria and its value as an outcome measure in chronic kidney disease. Br J Clin Pharmacol. 2013;76:516\u201323.","journal-title":"Br J Clin Pharmacol"},{"key":"2536_CR4","doi-asserted-by":"publisher","first-page":"e207","DOI":"10.1371\/journal.pmed.0050207","volume":"5","author":"V Perkovic","year":"2008","unstructured":"Perkovic V, Verdon C, Ninomiya T, Barzi F, Cass A, Patel A, et al. The relationship between proteinuria and coronary risk: a systematic review and meta-analysis. PLoS Med. 2008;5:e207.","journal-title":"PLoS Med"},{"key":"2536_CR5","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"PE Stevens","year":"2024","unstructured":"Stevens PE, Ahmed SB, Carrero JJ, Foster B, Francis A, Hall RK, et al. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105:S117\u2013S314.","journal-title":"Kidney Int"},{"key":"2536_CR6","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861\u20139.","journal-title":"N Engl J Med"},{"key":"2536_CR7","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851\u201360.","journal-title":"N Engl J Med"},{"key":"2536_CR8","doi-asserted-by":"publisher","first-page":"ii194","DOI":"10.1093\/ndt\/gfw440","volume":"32","author":"D Bolignano","year":"2017","unstructured":"Bolignano D, Zoccali C. Non-proteinuric rather than proteinuric renal diseases are the leading cause of end-stage kidney disease. Nephrol Dial Transpl. 2017;32:ii194\u20139.","journal-title":"Nephrol Dial Transpl"},{"key":"2536_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-55827-7","volume":"14","author":"T Tanaka","year":"2024","unstructured":"Tanaka T, Maruyama S, Chishima N, Akiyama H, Shimamoto K, Inokuchi S, et al. Population characteristics and diagnosis rate of chronic kidney disease by eGFR and proteinuria in Japanese clinical practice: an observational database study. Sci Rep. 2024;14:5172.","journal-title":"Sci Rep"},{"key":"2536_CR10","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1001\/jama.285.21.2719","volume":"285","author":"LY Agodoa","year":"2001","unstructured":"Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, et al. African American Study of Kidney Disease and Hypertension (AASK) study group. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001;285:2719\u201328.","journal-title":"JAMA"},{"key":"2536_CR11","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1093\/ndt\/gfac041","volume":"38","author":"T Imasawa","year":"2023","unstructured":"Imasawa T, Saito C, Kai H, Iseki K, Kazama JJ, Shibagaki Y, et al. Long-term effectiveness of a primary care practice facilitation program for chronic kidney disease management: an extended follow-up of a cluster-randomized FROM-J study. Nephrol Dial Transpl. 2023;38:158\u201366.","journal-title":"Nephrol Dial Transpl"},{"key":"2536_CR12","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436\u201346.","journal-title":"N Engl J Med"},{"key":"2536_CR13","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"WG Herrington","year":"2023","unstructured":"Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388:117\u201327.","journal-title":"N Engl J Med"},{"key":"2536_CR14","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.2337\/dc21-1081","volume":"44","author":"H Nagasu","year":"2021","unstructured":"Nagasu H, Yano Y, Kanegae H, Heerspink HJL, Nangaku M, Hirakawa Y, et al. Kidney outcomes associated with SGLT2 inhibitors versus other glucose-lowering drugs in real-world clinical practice: the Japan chronic kidney disease database. Diabetes Care. 2021;44:2542\u201351.","journal-title":"Diabetes Care"},{"key":"2536_CR15","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1124\/pr.59.3.3","volume":"59","author":"H Kobori","year":"2007","unstructured":"Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev. 2007;59:251\u201387.","journal-title":"Pharmacol Rev"},{"key":"2536_CR16","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.amjmed.2003.09.034","volume":"116","author":"UC Brewster","year":"2004","unstructured":"Brewster UC, Perazella MA. The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Am J Med. 2004;116:263\u201372.","journal-title":"Am J Med"},{"key":"2536_CR17","doi-asserted-by":"publisher","first-page":"F1295","DOI":"10.1152\/ajprenal.00471.2015","volume":"310","author":"FA Casare","year":"2016","unstructured":"Casare FA, Thieme K, Costa-Pessoa JM, Rossoni LV, Couto GK, Fernandes FB, et al. Renovascular remodeling and renal injury after extended angiotensin II infusion. Am J Physiol Ren Physiol. 2016;310:F1295\u2013307.","journal-title":"Am J Physiol Ren Physiol"},{"key":"2536_CR18","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/ndt\/gfi265","volume":"21","author":"M Ruiz-Ortega","year":"2006","unstructured":"Ruiz-Ortega M, Rup\u00e9rez M, Esteban V, Rodr\u00edguez-Vita J, S\u00e1nchez-L\u00f3pez E, Carvajal G, et al. Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases. Nephrol Dial Transpl. 2006;21:16\u201320.","journal-title":"Nephrol Dial Transpl"},{"key":"2536_CR19","volume":"2014","author":"M Pacurari","year":"2014","unstructured":"Pacurari M, Kafoury R, Tchounwou PB, Ndebele K. The renin-angiotensin-aldosterone system in vascular inflammation and remodeling. Int J Inflam. 2014;2014:689360.","journal-title":"Int J Inflam"},{"key":"2536_CR20","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/s41440-018-0116-3","volume":"42","author":"E Mishima","year":"2019","unstructured":"Mishima E, Haruna Y, Arima H. Renin-angiotensin system inhibitors in hypertensive adults with non-diabetic CKD with or without proteinuria: a systematic review and meta-analysis of randomized trials. Hypertens Res. 2019;42:469\u201382.","journal-title":"Hypertens Res"},{"key":"2536_CR21","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1161\/HYPERTENSIONAHA.124.23184","volume":"81","author":"R Shulman","year":"2024","unstructured":"Shulman R, Yang W, Cohen DL, Reese PP, Cohen JB, CRIC Study Investigators. Cardiac effects of renin-angiotensin system inhibitors in nonproteinuric CKD. Hypertension. 2024;81:2082\u201390.","journal-title":"Hypertension"},{"key":"2536_CR22","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1046\/j.1523-1755.2003.00840.x","volume":"63","author":"G D\u2019Amico","year":"2003","unstructured":"D\u2019Amico G, Bazzi C. Pathophysiology of proteinuria. Kidney Int. 2003;63:809\u201325.","journal-title":"Kidney Int"},{"key":"2536_CR23","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/2180373","volume":"2018","author":"S Mihai","year":"2018","unstructured":"Mihai S, Codrici E, Popescu ID, Enciu AM, Albulescu L, Necula LG, et al. Inflammation-related mechanisms in chronic kidney disease prediction, progression, and outcome. J Immunol Res. 2018;2018:2180373.","journal-title":"J Immunol Res"},{"key":"2536_CR24","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41392-023-01379-7","volume":"8","author":"R Huang","year":"2023","unstructured":"Huang R, Fu P, Ma L. Kidney fibrosis: from mechanisms to therapeutic medicines. Signal Transduct Target Ther. 2023;8:129.","journal-title":"Signal Transduct Target Ther"},{"key":"2536_CR25","doi-asserted-by":"crossref","unstructured":"Shulman R, Yang W, Cohen DL, Reese PP, Cohen JB. CRIC Study Investigators. Renin-Angiotensin system inhibitors in patients with non-proteinuric chronic kidney disease and kidney outcomes: Findings from the CRIC Study. Kidney Med. 2025;8:101159.","DOI":"10.1016\/j.xkme.2025.101159"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02536-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02536-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02536-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T22:02:16Z","timestamp":1775426536000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02536-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2536"],"URL":"https:\/\/doi.org\/10.1038\/s41440-025-02536-x","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"assertion":[{"value":"11 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"SM has received speaker honoraria from Alexion Pharma, Mitsubishi Tanabe Pharma, AstraZeneca, Ono Pharmaceutical, Kyowa Kirin, Torii Pharmaceutical, Otsuka Pharmaceutical, and Nippon Boehringer Ingelheim, received research funding for collaborative research from Rohto Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma, Zenyaku Kogyo, and Nipro Corporation, and received educational donations from Otsuka Pharmaceutical and Torii Pharmaceutical. JW receives speaker honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Kyowa Kirin, Novo Nordisk, and Mitsubishi Tanabe. KY has received speaker honoraria from AstraZeneca, Behringer Ingelheim, Otsuka, Kyowa-Kirin, Tanabe Mitsubishi, and received research funding for collaborative research from Kyowa-Kirin, Tanabe Mitsubishi, and Kaneka.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}